GlobeNewswire PharmaceuticalsCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 19:15:00·⟳ 抓取 19:15:50·⚡ 决策 09-01 20:34:45 +1h18m·55.9 天前
Kura Oncology宣布9月参加三场投资者会议
事件为例行投关会议日程公告，不改变公司药品权益、商业化进展、收入预期或风险状态，缺少可交易催化。
📄 原文GlobeNewswire Pharmaceuticals↗ 原文
Kura Oncology to Participate in Three Investor Conferences in September
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused o…
不做 Kura Oncology, Inc.（KURA.US）
例行投关会议日程公告，没有新增临床、监管、销售、合作或财务事实，方向和edge均不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Kura Oncology公告管理层将在9月参加三场医疗健康投资者会议并提供 webcast；正文没有披露临床、监管、销售、合作、融资或指引更新。该类日程公告通常只是未来交流安排，当前事实不足以形成做多或做空的正期望。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
主要风险
- 后续会议若披露新的KOMZIFTI销售、管线或监管信息，需要作为新事件重新评估。
先例如何影响了这次决策
对本次决策的影响:确认本次不设入场、止盈或止损。
方向:例行投资者会议日程公告缺少方向性，先例研究不会改变不交易结论。
涨幅量级:无可用于幅度校准的基本面冲击。
形态:无交易方向，因此未使用历史价格反应作为入场依据。
原文全文
展开原文 · 1,498 字
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences:
Wells Fargo Healthcare Conference
September 8, 2026
3:45 p.m. ET / 12:45 p.m. PT
Cantor Global Healthcare Conference
September 9, 2026
9:10 a.m. ET / 6:10 a.m. PT
Morgan Stanley Global Healthcare Conference
September 16, 2026
7:45 a.m. ET / 4:45 a.m. PT
Live audio webcasts will be available in the Investors section of Kura’s website at
https://kuraoncology.com/
, with archived replays available following all three events.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory
NPM1
-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at
https://kuraoncology.com/
and follow us on
X
and
LinkedIn
.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
Wells Fargo Healthcare Conference
September 8, 2026
3:45 p.m. ET / 12:45 p.m. PT
Cantor Global Healthcare Conference
September 9, 2026
9:10 a.m. ET / 6:10 a.m. PT
Morgan Stanley Global Healthcare Conference
September 16, 2026
7:45 a.m. ET / 4:45 a.m. PT
Live audio webcasts will be available in the Investors section of Kura’s website at
https://kuraoncology.com/
, with archived replays available following all three events.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory
NPM1
-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at
https://kuraoncology.com/
and follow us on
X
and
.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。